References
Yamato G, Deguchi T, Terui K, Toki T, Watanabe T, Imaizumi T, et al.
Predictive factors for the development of leukemia in patients with
transient abnormal myelopoiesis and Down syndrome. Leukemia.
2021;35(5):1480–4.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient abnormal
myelopoiesis and AML in Down syndrome: An update. Curr Hematol Malig
Rep. 2016;11(5):333–41
Tunstall O, Bhatnagar N, James B, Norton A, O’Marcaigh AS, Watts T, et
al. Guidelines for the investigation and management of Transient
Leukaemia of Down Syndrome. Br J Haematol. 2018;182(2):200–11
Klusmann J-H, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake
C, et al. Treatment and prognostic impact of transient leukemia in
neonates with Down syndrome. Blood. 2008;111(6):2991–8.
Gamis AS, Smith FO. Transient myeloproliferative disorder in children
with Down syndrome: clarity to this enigmatic disorder. Br J Haematol.
2012;159(3):277–87.
Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term results of
an ultra low-dose cytarabine-based regimen for the treatment of acute
megakaryoblastic leukaemia in children with Down syndrome. Br J
Haematol. 2006; 133: 646–648
Labuhn M, Perkins K, Matzk S, et al. Mechanisms of Progression of
Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with
Down Syndrome. Cancer Cell . 2019;36(2):123-138.e10.
doi:10.1016/j.ccell.2019.06.007